A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

NCT00034619 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: ALIMTA
DRUG: Oxaliplatin

Sponsor

Eli Lilly and Company